The cost of Ingrezza (valbenazine) with insurance can vary significantly depending on the specific insurance plan, deductible, copay, and coinsurance. However, without insurance, the list price of Ingrezza is approximately $7,500 for a 30-day supply.
What helps lower Ingrezza costs for patients?
For eligible patients, there are programs that can help reduce out-of-pocket expenses for Ingrezza. The manufacturer, Neurocrine Biosciences, offers a Savings Program that can provide eligible commercially insured patients with as little as a $10 copay per month for their prescription [1]. Eligibility requirements apply, and the program has certain limitations [1]. Patients should check the Neurocrine Biosciences website or contact their healthcare provider for specific details on how to enroll and what criteria they need to meet.
How do pharmaceutical companies decide Ingrezza's price?
The pricing of a drug like Ingrezza is influenced by several factors, including the research and development costs, manufacturing expenses, clinical trial data, the drug's efficacy and therapeutic value, and the market landscape. The significant investment required for drug discovery, clinical testing, and regulatory approval contributes to the initial pricing. Additionally, the unmet medical need the drug addresses and its impact on patient quality of life are considered.
When does Ingrezza's patent protection end?
Ingrezza is protected by patents that limit the ability of other companies to produce generic versions. Information regarding the specific expiry dates of these patents is available through resources like DrugPatentWatch.com [2]. Patent expiration is crucial as it typically opens the door for generic competition, which can lead to a significant reduction in drug costs.
What are the alternatives to Ingrezza for tardive dyskinesia?
For tardive dyskinesia, other treatment options are available, though they may differ in their mechanism of action and efficacy. These alternatives might include other prescription medications that target different neurotransmitter systems involved in movement disorders. Patients should discuss all available treatment options with their healthcare provider to determine the most suitable therapy based on their individual medical needs and response to treatment.